Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data

Gils Roex; Tom Feys; Yves Beguin; Tessa Kerre; Xavier Poiré; Philippe Lewalle; Peter Vandenberghe; Dominique Bron; Sébastien Anguille

doi:10.3390/pharmaceutics12020194

Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data

Pharmaceutics. 2020 Feb 24;12(2):194. doi: 10.3390/pharmaceutics12020194.

Authors

Gils Roex¹, Tom Feys², Yves Beguin³, Tessa Kerre⁴, Xavier Poiré⁵, Philippe Lewalle⁶, Peter Vandenberghe⁷, Dominique Bron⁶, Sébastien Anguille^{1

8}

Affiliations

¹ Tumor Immunology Group, Laboratory of Experimental Hematology, Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, 2650 Edegem, Belgium.
² Ariez International BV, 9000 Ghent, Belgium.
³ Department of Hematology, University of Liège, 4000 Liège, Belgium.
⁴ Department of Hematology, University Hospital Ghent, 9000 Ghent, Belgium.
⁵ Faculty of Medicine and Dentistry, Université Catholique de Louvain, 1200 Woluwe-Saint-Lambert, Belgium.
⁶ Department of Hematology, Institut Jules Bordet, 1000 Brussels, Belgium.
⁷ Department of Hematology, University Hospitals Leuven, 3000 Leuven, Belgium.
⁸ Center for Cell Therapy & Regenerative Medicine (CCRG) and Division of Hematology, Antwerp University Hospital, 2650 Edegem, Belgium.

Abstract

Chimeric antigen receptor (CAR)-T-cell therapy is an innovative form of adoptive cell therapy that has revolutionized the treatment of certain hematological malignancies, including B-cell non-Hodgkin lymphoma (NHL) and B-cell acute lymphoblastic leukemia (ALL). The treatment is currently also being studied in other B-cell neoplasms, including multiple myeloma (MM) and chronic lymphocytic leukemia (CLL). CD19 and B-cell maturation antigen (BCMA) have been the most popular target antigens for CAR-T-cell immunotherapy of these malignancies. This review will discuss the efficacy and toxicity data from the pivotal clinical studies of CD19- and BCMA-targeted CAR-T-cell therapies in relapsed/refractory B-cell malignancies (NHL, ALL, CLL) and MM, respectively.

Keywords: B-cell malignancies; BCMA; CAR-T cells; CD19; immunotherapy.

Publication types

Review